Advertisement
The record date for the purpose of determining shareholders entitled to receive notice of, and to vote at, the Special Meeting is September 14, 2009.
Advertisement
The MDS Board of Directors believes the proposed sale of MDS Analytical Technologies to Danaher is in the best interests of the Company and its shareholders, and unanimously recommends that shareholders vote in favor of the sale.
MDS expects that a Management Proxy Circular for the shareholder meeting will be mailed to shareholders later this month and will be available at www.sedar.com, www.sec.gov/edgar.shtml and www.mdsinc.com. The Management Proxy Circular will provide important information about the proposed transaction as well as information related to voting procedures.
About MDS
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 4,200 highly skilled people in 13 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
SOURCE MDS Inc.
